nrix-20231211
0001549595false00015495952023-12-112023-12-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
FORM 8-K
___________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 11, 2023
___________________________________________
NURIX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
___________________________________________
Delaware001-3939827-0838048
(State or Other Jurisdiction
of Incorporation or Organization)
(Commission
File Number)
(IRS Employer
Identification No.)
1700 Owens StreetSuite 205
San FranciscoCalifornia
94158
(Address of Principal Executive Offices)(Zip Code)
(415660-5320
(Registrant’s Telephone Number, Including Area Code) 
N/A
(Former Name or Former Address, if Changed Since Last Report)
___________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: 
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareNRIXNasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 8.01    Other Events.
On December 11, 2023, Nurix Therapeutics, Inc. (the “Company”) issued a press release announcing the presentation at the 65th American Society of Hematology Annual Meeting and Exposition (the “ASH Annual Meeting”) of positive clinical data from the Company’s novel Bruton's tyrosine kinase (BTK) degrader programs, NX-5948 and NX-2127. As previously announced, the Company will host a webcast at 8:30 p.m. Pacific Time (11:30 p.m. Eastern Time) on December 11, 2023, to review the data presented at the ASH Annual Meeting from its BTK degrader programs. A copy of the press release, which includes the data presented at the ASH Annual Meeting, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits.
(d)Exhibits
The following exhibits are filed herewith and this list is intended to constitute the exhibit index:
Exhibit No.Exhibit Title or Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NURIX THERAPEUTICS, INC.
Date: December 11, 2023By:/s/ Christine Ring
Christine Ring, Ph.D., J.D.
Chief Legal Officer
3